LIFECORE BIOMEDICAL, INC. Preferred Stock Dividends, Income Statement Impact
LIFECORE BIOMEDICAL, INC. (LFCR) reported Preferred Stock Dividends, Income Statement Impact of $924.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. preferred stock dividends, income statement impact for the quarter ending 2026-06-30 was $924.00K.
- LIFECORE BIOMEDICAL, INC. preferred stock dividends, income statement impact for the quarter ending 2026-03-31 was $907.00K.
- LIFECORE BIOMEDICAL, INC. preferred stock dividends, income statement impact for the quarter ending 2025-09-30 was $874.00K.
- LIFECORE BIOMEDICAL, INC. preferred stock dividends, income statement impact for the quarter ending 2025-05-25 was $852.00K.
- LIFECORE BIOMEDICAL, INC. preferred stock dividends, income statement impact for fiscal 2025 was $3.32M.
- LIFECORE BIOMEDICAL, INC. preferred stock dividends, income statement impact for fiscal 2024 was $0.00.
| Period end | Preferred Stock Dividends, Income Statement Impact 1 month | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 3 month as first filed | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 7 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $924.00K 10-Q · filed 2026-08-05 | $1.83M 10-Q · filed 2026-08-05 | |||||
| 2026-03-31 | $907.00K 10-Q · filed 2026-05-06 | ||||||
| 2025-12-31 | $2.05M 10-KT · filed 2026-03-16 | ||||||
| 2025-09-30 | $874.00K 10-Q · filed 2025-11-06 | ||||||
| 2025-06-30 | $286.00K 10-KT · filed 2026-03-16 | ||||||
| 2025-05-25 | $852.00K 10-Q · filed 2026-08-05 | $1.69M 10-Q · filed 2026-08-05 | $3.32M 10-KT · filed 2026-03-16 | ||||
| 2025-02-23 | $837.00K 10-Q · filed 2026-05-06 | $2.47M 10-Q · filed 2025-04-03 | $2.47M 10-Q · filed 2025-04-03 | ||||
| 2024-12-31 | $1.90M 10-KT · filed 2026-03-16 | ||||||
| 2024-08-25 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | ||||
| 2024-05-26 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 10-KT · filed 2026-03-16 | ||||
| 2024-02-25 | $0.00 10-Q · filed 2025-04-03 | $0.00 10-Q · filed 2025-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |